Comparison between ticagrelor versus clopidogrel in long term outcomes of Taiwanese diabetic subjects with acute coronary syndrome undergoing successful revascularization: From TSOC ACS-DM registry

Although previous clinical trials demonstrated that ticagrelor could reduce cardiovascular events and mortality versus clopidogrel in patients with acute coronary syndrome (ACS), the real-world evidence of its clinical impacts on East Asian Diabetic population has rarely been investigated. Between N...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cheng-An, Hsieh, Yi-Chen, Huang, Chun-Yao, Liu, Ju-Chi, Hsieh, Ming-Hsiung, Lin, Yung-Kuo, Yeh, Jong-Shiuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220397/
https://www.ncbi.nlm.nih.gov/pubmed/32384446
http://dx.doi.org/10.1097/MD.0000000000019969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220397/
https://www.ncbi.nlm.nih.gov/pubmed/32384446
http://dx.doi.org/10.1097/MD.0000000000019969

Ejemplares similares